March 2016 ARTICLE LIST >>
PharmaTutor (March- 2016)
Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 3)
Received On: 16/09/2015; Accepted On: 29/09/2015; Published On: 01/03/2016
AUTHORS:
Rohit A. Patil*, Rajendra C. Doijad, Pravin D.Lade, Pournima S. Sankpal
Department of Pharmaceutical Chemistry,
Shree Santkrupa College of Pharmacy, Ghogaon, Karad, Maharashtra, India
*rohitpharma3250@gmail.com
ABSTRACT: Simple, sensitive and specific spectrophotometric method were developed and validated for quantification of CAPECITABINE (CAP) by difference spectroscopy. CAP exhibits a substantial difference in absorbance in the two solvents that is in 0.01 N HCL and 0.01 N NAOH at 295 nm. Beer’s law was obeyed in the concentration range of 1 to 20 μg ml-1for CAP. Results of tablet analysis showed standard deviation in the range of 98.42 to 101.95 % for CAP which indicate repeatability of the method. The results indicated excellent recoveries ranging from 98.45 to 101.70 % for CAP with a mean of 99.12 %. Recoveries obtained do not differ significantly from 100% showed that there was no interference from the common excipients used in the tablet formulation indicating accuracy and reliability of the method.
How to cite this article: Patil RA, Doijad RC, Lade PD, Sankpal PS; Difference spectrophotometric estimation of Capecitabine from tablet dosage form; PharmaTutor; 2016; 4(3); 17-21
[ABSTRACT WITH CITATION] [VIEW AS HTML]
REFERENCES:
1. Jemal A et al; Cancer Statistics; Cancer J Clin.; 2009; 59(4); 225-249
2. Herman J.M.; Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation after pancreatic oduodenectomy for Ductal Adenocarcinoma of the pancreas; Journal of Clinical Oncology; 2008; 26(21); 3503-3510
3. VanCutsem E.; A phase IB dose-escalation study of Erlotinib, Capecitabine and Oxaliplatin in Metastatic Colorectal Cancer Patients; Ann Oncology; 2008; 19(2); 332-339
4. Neoptolemos J.P.; A Multicenter, International, Open-Label, Randomized, Controlled Phase III trial of adjuvant 5-fluorouracil/folinic acid (5-fu/fa) versus Gemcitabine (gem) in patients with Restricted Pancreatic Ductal Adenocarcinoma; Journal of Clinical Oncology; 2009; 27(18s); LBA4505
5. Yanagisawa K.F.; Antitumor activity of Erlotinib in combination with Capecitabine in Human Tumor Xenograft Models; Cancer ChemotherPharmacol.; 2006; 57(5); 693-702
6. Twelves C.; Erlotinib in combination with Capecitabine and Docetaxel in patients with Metastatic Breast Cancer: a dose- escalation study; European Journal of Cancer; 2008; 44(3); 419-426
7. Besnard T; Optimized blood sampling with cytidine deaminase inhibitor for improve analysis of Capecitabin Metabolites; Journal of Chromatography B Analyst Technology Biomed Life Sciences; 2008; 870(1); 117-120
8. Eloubeidi. M.A.; Phase I study of Capecitabine with concomitant radiotherapy for patients with locally advanced Pancreatic Cancer: expression analysis of genes related to outcome; Journal of Clinical Oncology; 2005; 23(34); 8679-8687.
9. Zufia L.; Simple Determination of Capecitabine and its metabolites by Liquid Chromatography with Ultraviolet Detection in a single injection; Journal of chromatography B; 2004; 809(1); 51- 58
10. Sylvie M.; Simultaneous Determination of Capecitabine and its metabolites by HPLC and Mass Spectrometry for Preclinical and Clinical studies; Journal of chromatography B; 2005; 826(1-2); 232-237
11. Wang S; Development of a sensitive and selective LC/MS/MS method for the determination of α-fluoro-β-alanine-5-fluoro uracil and Capecitabine in human plasma; Journal of chromatography B; 2005; 265; 32-37
12. Xu Yan; Liquid Chromatography-Mass Spectrometry method for the analysis of the anti-cancer agent Capecitabine and its nucleoside metabolites in human plasma; Journal of chromatography B; 2003; 783(1), 273- 285
13. Desmoulin F.; Isolaton of an unknown metabolite of Capecitabine, an oral 5-fluorouracil prodrug, and its identification by Nuclear Magnetic Resonance and Liquid Chromatography-Tandem Mass Spectrometry as a glucuroconjugate of 5’- deoxy-5-fluorocytidine, namely 2’-(β-Dglucuronic acid)-5’-deoxy-5-fluorocytidine; Journal of chromatography B; 2003; 792(2); 323-332
14. Gutens G.; Hyphenated Techniques in Anticancer Drug Monitoring II. Liquid Chromatography-Mass Spectrometry and Capillary Electrophoresis; Journal of chromatography A; 2002; 976(1-2); 239-247
15. Patil P.S., More H.N.; Difference spectroscopic estimation of Enalapril maleate from tablet dosage form; International journal of Research in Pharmaceutical and Biomedical Sciences; 2011; 2(2); 629-633
16. Sankpal Poournima., Doijad Rajendra, Suryawanshi Gayatri, Patil Priyanka, Pathan Aasma; Simple Quantitative Method Development and Validation of Capecitabine in Pure Form and Pharmaceutical Dosage Forms by UV-Spectroscopy; 2012 (1).
17. ICH guideline Q2 (R1); Validation of Analytical Procedures: Text and Methodology; 2005
.png)
